Matthew F. Brown

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

Paul S. Changelian, Mark E. Flanagan, Douglas J. Ball et al. · Science · 2003 · 667 citations · Full text

Immunology, Cell Death, Immunotherapy +21

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

Maria Dêbiec‐Rychter, Herlinde Dumez, Ian Judson et al. · European Journal of Cancer · 2004 · 442 citations

Surgical Oncology, Bone Sarcoma Group, Gastrointestinal Oncology +8

Delineating the role of cooperativity in the design of potent PROTACs for BTK

Adelajda Zorba, Chuong Nguyen, Yingrong Xu et al. · Proceedings of the National Academy of Sciences · 2018 · 409 citations · Full text

Engineering, Molecular Biology, Organic Chemistry +18

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

Mark E. Flanagan, Todd A. Blumenkopf, William H. Brissette et al. · Journal of Medicinal Chemistry · 2010 · 331 citations · Full text

Immunology, Janus Tyrosine Kinases, Immunotherapy +19

Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors

Mark E. Flanagan, J. A. Abramite, Dennis P. Anderson et al. · Journal of Medicinal Chemistry · 2014 · 318 citations

Combinatorial Chemistry, Drug Target, Thiol-reactive Covalent Inhibitors +17